# Heartflow, Inc.: financial statements, quarterly

HTFL · Nasdaq · CIK 1464521 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/htfl.md) · [Financials](/companies/htfl/financials.md) · [Filings](/companies/htfl/filings.md) · [Insiders](/companies/htfl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/htfl/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [31.1](/filings/0001464521-25-000012.md) | [32.9](/filings/0001464521-25-000019.md) | [35.0 d](/filings/0001464521-26-000042.md) | [37.2](/filings/0001464521-26-000071.md) | [43.4](/filings/0001464521-26-000131.md) | [46.3](/filings/0001464521-25-000019.md) | [49.1 d](/filings/0001464521-26-000042.md) | [52.6](/filings/0001464521-26-000071.md) | [64.1](/filings/0001464521-26-000131.md) |
| Cost of revenue | $m | not reported | [7.2](/filings/0001464521-25-000012.md) | [8.0](/filings/0001464521-25-000019.md) | [8.7 d](/filings/0001464521-26-000042.md) | [9.3](/filings/0001464521-26-000071.md) | [10.6](/filings/0001464521-26-000131.md) | [10.9](/filings/0001464521-25-000019.md) | [10.1 d](/filings/0001464521-26-000042.md) | [10.4](/filings/0001464521-26-000071.md) | [10.9](/filings/0001464521-26-000131.md) |
| Gross profit | $m | not reported | [23.8](/filings/0001464521-25-000012.md) | [24.9](/filings/0001464521-25-000019.md) | [26.3 d](/filings/0001464521-26-000042.md) | [27.9](/filings/0001464521-26-000071.md) | [32.8](/filings/0001464521-26-000131.md) | [35.4](/filings/0001464521-25-000019.md) | [39.1 d](/filings/0001464521-26-000042.md) | [42.2](/filings/0001464521-26-000071.md) | [53.2](/filings/0001464521-26-000131.md) |
| Research and development | $m | not reported | [9.9](/filings/0001464521-25-000012.md) | [11.9](/filings/0001464521-25-000019.md) | [12.3 d](/filings/0001464521-26-000042.md) | [13.9](/filings/0001464521-26-000071.md) | [15.0](/filings/0001464521-26-000131.md) | [17.3](/filings/0001464521-25-000019.md) | [18.7 d](/filings/0001464521-26-000042.md) | [21.6](/filings/0001464521-26-000071.md) | [26.3](/filings/0001464521-26-000131.md) |
| Selling, general and administrative | $m | not reported | [28.1](/filings/0001464521-25-000012.md) | [28.0](/filings/0001464521-25-000019.md) | [30.0 d](/filings/0001464521-26-000042.md) | [31.5](/filings/0001464521-26-000071.md) | [31.5](/filings/0001464521-26-000131.md) | [33.2](/filings/0001464521-25-000019.md) | [38.1 d](/filings/0001464521-26-000042.md) | [42.6](/filings/0001464521-26-000071.md) | [44.8](/filings/0001464521-26-000131.md) |
| Operating income | $m | not reported | [(14.2)](/filings/0001464521-25-000012.md) | [(14.9)](/filings/0001464521-25-000019.md) | [(16.1) d](/filings/0001464521-26-000042.md) | [(17.5)](/filings/0001464521-26-000071.md) | [(13.7)](/filings/0001464521-26-000131.md) | [(15.1)](/filings/0001464521-25-000019.md) | [(17.8) d](/filings/0001464521-26-000042.md) | [(29.5)](/filings/0001464521-26-000071.md) | [(17.9)](/filings/0001464521-26-000131.md) |
| Interest expense | $m | not reported | [6.1](/filings/0001464521-25-000012.md) | [5.3](/filings/0001464521-25-000019.md) | [5.2 d](/filings/0001464521-26-000042.md) | [5.1](/filings/0001464521-26-000071.md) | [6.6](/filings/0001464521-26-000131.md) | [3.5](/filings/0001464521-25-000019.md) | [0.0 d](/filings/0001464521-26-000042.md) | [0.0](/filings/0001464521-26-000071.md) | [0.0 d](/filings/0001464521-26-000131.md) |
| Income tax | $m | not reported | [0.1](/filings/0001464521-25-000012.md) | [0.0](/filings/0001464521-25-000019.md) | [0.0 d](/filings/0001464521-26-000042.md) | not reported | [0.1](/filings/0001464521-26-000131.md) | [0.0](/filings/0001464521-25-000019.md) | [(0.2) d](/filings/0001464521-26-000042.md) | [0.0](/filings/0001464521-26-000071.md) | [0.0](/filings/0001464521-26-000131.md) |
| Net income | $m | [(20.9)](/filings/0001464521-25-000019.md) | [(23.4)](/filings/0001464521-25-000019.md) | [(19.1)](/filings/0001464521-25-000019.md) | [(33.0) d](/filings/0001464521-26-000042.md) | [(32.3)](/filings/0001464521-26-000131.md) | [(9.2)](/filings/0001464521-26-000131.md) | [(50.9)](/filings/0001464521-25-000019.md) | [(24.4) d](/filings/0001464521-26-000042.md) | [(27.4)](/filings/0001464521-26-000131.md) | [(15.7)](/filings/0001464521-26-000131.md) |
| Diluted EPS | $ per share | not reported | [(4.66)](/filings/0001464521-25-000012.md) | [(3.43)](/filings/0001464521-25-000019.md) | not reported | [(5.25)](/filings/0001464521-26-000071.md) | [(1.46)](/filings/0001464521-26-000131.md) | [(1.04)](/filings/0001464521-25-000019.md) | not reported | [(0.32)](/filings/0001464521-26-000071.md) | [(0.18)](/filings/0001464521-26-000131.md) |
| Basic EPS | $ per share | not reported | [(4.66)](/filings/0001464521-25-000012.md) | [(3.43)](/filings/0001464521-25-000019.md) | not reported | [(5.25)](/filings/0001464521-26-000071.md) | [(1.46)](/filings/0001464521-26-000131.md) | [(1.04)](/filings/0001464521-25-000019.md) | not reported | [(0.32)](/filings/0001464521-26-000071.md) | [(0.18)](/filings/0001464521-26-000131.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [123](/filings/0001464521-26-000042.md) | not reported | [75.4](/filings/0001464521-25-000012.md) | [64.7](/filings/0001464521-25-000019.md) | [51.4](/filings/0001464521-26-000042.md) | [110](/filings/0001464521-26-000071.md) | [80.2](/filings/0001464521-26-000131.md) | [291](/filings/0001464521-25-000019.md) | [44.8](/filings/0001464521-26-000131.md) | [19.7](/filings/0001464521-26-000071.md) | [34.4](/filings/0001464521-26-000131.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [82.3](/filings/0001464521-26-000042.md) | not reported | [118](/filings/0001464521-25-000012.md) | [328](/filings/0001464521-25-000019.md) | [220](/filings/0001464521-26-000131.md) | [212](/filings/0001464521-26-000071.md) | [224](/filings/0001464521-26-000131.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [119](/filings/0001464521-26-000042.md) | not reported | [159](/filings/0001464521-25-000012.md) | [364](/filings/0001464521-25-000019.md) | [359](/filings/0001464521-26-000131.md) | [344](/filings/0001464521-26-000071.md) | [344](/filings/0001464521-26-000131.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [33.6](/filings/0001464521-26-000042.md) | not reported | [32.9](/filings/0001464521-25-000012.md) | [37.8](/filings/0001464521-25-000019.md) | [42.4](/filings/0001464521-26-000131.md) | [38.0](/filings/0001464521-26-000071.md) | [44.1](/filings/0001464521-26-000131.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [210](/filings/0001464521-26-000042.md) | not reported | [286](/filings/0001464521-25-000012.md) | [110](/filings/0001464521-25-000019.md) | [58.8](/filings/0001464521-26-000131.md) | [58.3](/filings/0001464521-26-000071.md) | [64.7](/filings/0001464521-26-000131.md) |
| Shareholders' equity | $m | [(694)](/filings/0001464521-26-000042.md) | [(778)](/filings/0001464521-26-000042.md) | [(796)](/filings/0001464521-25-000019.md) | [(815)](/filings/0001464521-25-000019.md) | [(831)](/filings/0001464521-25-000019.md) | [(859)](/filings/0001464521-26-000131.md) | [(889)](/filings/0001464521-26-000131.md) | [(895)](/filings/0001464521-26-000131.md) | [255](/filings/0001464521-25-000019.md) | [301](/filings/0001464521-26-000131.md) | [286](/filings/0001464521-26-000131.md) | [280](/filings/0001464521-26-000131.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.3) d](/filings/0001464521-25-000019.md) | [(14.0) d](/filings/0001464521-26-000042.md) | [(13.2)](/filings/0001464521-26-000071.md) | [(27.3) d](/filings/0001464521-26-000131.md) | [(3.0) d](/filings/0001464521-25-000019.md) | [(10.6) d](/filings/0001464521-26-000042.md) | [(30.1)](/filings/0001464521-26-000071.md) | [(8.6) d](/filings/0001464521-26-000131.md) |
| Capital expenditure | $m | [1.0 d](/filings/0001464521-25-000019.md) | [0.3 d](/filings/0001464521-26-000042.md) | [1.1](/filings/0001464521-26-000071.md) | [0.8 d](/filings/0001464521-26-000131.md) | [1.2 d](/filings/0001464521-25-000019.md) | [1.9 d](/filings/0001464521-26-000042.md) | [1.9](/filings/0001464521-26-000071.md) | [1.9 d](/filings/0001464521-26-000131.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [5.0](/filings/0001464521-25-000012.md) | [5.6](/filings/0001464521-25-000019.md) | [6.2](/filings/0001464521-26-000071.md) | [6.3](/filings/0001464521-26-000131.md) | [49.1](/filings/0001464521-25-000019.md) | [85.6](/filings/0001464521-26-000071.md) | [86.4](/filings/0001464521-26-000131.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 86,953,627 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001464521-26-000131.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.